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Abstract
Purpose Many men with prostate cancer are asymptomatic,
diagnosed following prostate specific antigen (PSA) testing.
We investigate whether mode of detection, i.e. ‘PSA detected’
or ‘clinically detected’, was associated with psychological
wellbeing among prostate cancer survivors.
Methods A cross-sectional postal questionnaire was adminis-
tered in 2012 to 6559 prostate cancer (ICD10 C61) survivors
up to 18 years post-diagnosis, identified through population-
based cancer registries in Ireland. Psychological wellbeing
was assessed using the Depression Anxiety Stress Scale-21.
Logistic regression was used to investigate associations be-
tween mode of detection and depression, anxiety and stress,
adjusting for socio-demographic and clinical confounders.
Results The response rate was 54 % (3348/6262). Fifty-nine
percent of survivors were diagnosed with asymptomatic PSA-
tested disease. Prevalence of depression (13.8 vs 20.7 %;
p < 0.001), anxiety (13.6 vs 20.9 %; p < 0.001) and stress
(8.7 vs 13.8 %; p < 0.001) were significantly lower among
survivors diagnosed with PSA-detected, than clinically detect-
ed disease. After adjusting for clinical and socio-demographic
factors, survivors with clinically detected disease had signifi-
cantly higher risk of depression (odds ratio (OR) = 1.46 95 %
CI 1.18, 1.80; p = 0.001), anxiety (OR = 1.36 95 % CI 1.09,
1.68; p = 0.006) and stress (OR = 1.43 95 % CI 1.11, 1.85;
p = 0.006) than survivors with PSA-detected disease.
Conclusions These findings contribute to the ongoing debate
on benefits and risks of PSA testing and may be considered by
policy makers formulating population-based prostate cancer
screening policies. The relatively high prevalence of negative
psychological states among survivorsmeans that a ‘risk-adapted
approach’ should be implemented to screen survivors most at
risk of psychological morbidity for psychological health, and
mode of detection could be considered as a risk stratum.
Keywords Prostate cancer . Depression . Anxiety . Stress .
Prostate specific antigen . PSA . Screening
Introduction
Screening is a balance between benefit and risk [1].
Widespread use of prostate specific antigen (PSA) testing for
prostate cancer detection in general practice has stimulated
interest in whether population-based prostate cancer screening
programmes should be implemented [2–4]. Although PSA
testing has resulted in a decrease in cancer stage and grade
at detection [5, 6], its benefits regarding prostate cancer mor-
tality remain unresolved, with contradictory findings from two
randomised controlled trials, after 13 years follow-up [7, 8].
Furthermore, PSA testing carries substantial risks including
over-diagnosis and over-treatment [7, 9]. Screening may also
be associated with the risk of adverse psychological effects;
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PSA testing has been shown to adversely affect men’s short-
term psychological health by increasing prostate cancer-
related worry [10, 11]. Additionally, prevalence of depression
and anxiety is higher among men with prostate cancer than
age-matched controls without prostate cancer [12, 13].
However, the effect of being diagnosed with asymptomatic
prostate cancer via PSA testing on the psychological
wellbeing of survivors has not, to our knowledge, been
investigated.
To inform rational decision-making around PSA testing, it
is essential to have a comprehensive understanding of the
benefits and risks. To contribute to this understanding, we
aimed to investigate whether mode of detection (asymptom-
atic PSA detected vs symptomatic clinically detected) was
associated with the psychological health of prostate cancer
survivors, in a large, population-based study.
Methods
Setting
The Republic of Ireland (RoI) has a mixed public-private
healthcare system, and approximately half the population
has private health insurance. Northern Ireland (NI) has a pri-
marily public health system. Prostate cancer screening is not
recommended in either jurisdiction. The RoI had no national
guidelines until 2011, when the National Cancer Control
Programme recommended that men with a raised PSA have
a repeat PSA test after 6 weeks, followed by a biopsy referral
if the level remains raised [14]. The National Institute for
Health and Care Excellence (NICE) prostate cancer detection
guidelines (2008) advocate a repeat PSA test after 7 weeks
among men in NI [15]. There was evidence of unregulated,
opportunistic case finding in the RoI (1994–2005), PSA
screening in NI (1990–1999) and higher rates of PSA testing
in the RoI compared to NI [4, 6].
Participants
Methods from the PiCTure study were described previously
[16]. Briefly, a population-based sample of all men diagnosed
with invasive prostate cancer (ICD10 C61) between 1st
January 1995 and 31st March 2010, and alive in November
2011, was selected from the two population-based cancer reg-
istries in Ireland (n = 22,823). From this, a country-stratified
random sample of 12,322 men was selected. Healthcare pro-
fessionals screened men for eligibility to participate. Men
were eligible if they were (i) alive, (ii) aware of their diagno-
sis, (iii) well enough to complete a questionnaire, (iv) able to
understand English and (v) resident in RoI or NI. Six thousand
five hundred fifty-nine survivors, who were between 2 and
18 years post-diagnosis, were deemed eligible to receive a
questionnaire. Questionnaires were posted during April to
September 2012. Non-responders received up to two written
reminders and free-phone numbers were provided if help was
required.
Ethical approval
All procedures were in accordance with the ethical standards
of the Irish College of General Practitioners and the Office for
Research Ethics Committee NI and with the 1964 Helsinki
Declaration and its later amendments [17]. Research gover-
nance approval was obtained from the five NI Health Trusts.
Informed consent was obtained from all individual partici-
pants included in the study through return of completed ques-
tionnaires and/or consent forms.
Survey instrument
Men were asked how their prostate cancer was detected. They
were classified as having asymptomatic ‘PSA-detected’ dis-
ease if they answered ‘yes’ to any of the following statements:
‘I had no symptoms and myGP offered to test my PSA as part
of a general health check’ or ‘I had no symptoms and I asked
my GP to measure my PSA’, and as having symptomatic
‘clinically detected’ disease if they answered ‘yes’ to either
of the following statements: ‘I attended my GP with urinary
symptoms (e.g. urinating frequently, blood in urine)’ or ‘I
attended my GP with other symptoms (e.g. back pain, joint
pain)’. Respondents who provided free text descriptions were
categorised as asymptomatic PSA detected or symptomatic
clinically detected as appropriate. Men who endorsed both
asymptomatic and symptomatic statements (n = 171; 5 % all
respondents) were coded as symptomatic. Hereafter these
groups are referred to as PSA detected and clinically detected.
The questionnaire asked about treatment(s) received with
start and end dates, adverse physical effects experienced ‘ev-
er’ after treatment and ‘ongoing’ at questionnaire completion;
comorbid conditions at diagnosis and whether they were treat-
ed for depression following their prostate cancer diagnosis.
Content also included socio-demographic characteristics.
Psychological wellbeing, in the week prior to questionnaire
completion, was assessed using the 21 question version of the
Depression Anxiety Stress Scales (DASS-21). DASS-21 in-
cludes three sub-scales relating to self-reported negative emo-
tional states: depression, anxiety and stress [18]. Each sub-
scale comprises seven questions. Respondents were asked to
respond to each question along a 4-point Likert scale from 0
‘Did not apply to me at all’ to 3 ‘Applied to me very much, or
most of the time’. The depression scale assesses dysphoria,
hopelessness, devaluation of life, self-deprecation, lack of in-
terest/involvement, anhedonia and inertia. The anxiety scale
assesses autonomic arousal, skeletal muscle effects, situation-
al anxiety and subjective experience of anxious affect, and the
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stress scale assesses levels of chronic non-specific arousal,
difficulty relaxing, nervous arousal and being easily upset/
agitated, irritable/over-reactive and impatient [18]. The
Cronbach’s alpha value for the 7-item scales of DASS-21
ranges from 0.73 (anxiety) to 0.81 (stress and depression),
and it has adequate convergent and discriminate validity
[18.19].
Data handling
Scores for each DASS-21 subscale were calculated by sum-
ming scores for the relevant questions [18]. A maximum score
of 21 could be achieved for each subscale and scores were
doubled for analysis. Depression, anxiety and stress were
analysed separately, with scores reduced to binomial variables
for modelling. Respondents were categorised as having de-
pression, anxiety or stress if they scored ≥10, ≥8 or ≥15 on
the relevant subscale [18]. Men who completed all questions
on a sub-scale were included in analysis of that sub-scale.
A mutually exclusive primary treatment variable was con-
structed with categories radical prostatectomy (RP) with or
without other treatments, external beam radiotherapy
(EBRT) with concurrent androgen deprivation therapy
(ADT) but without RP, EBRT without concurrent ADT or
RP, brachytherapy (BT) without RP or EBRT, ADT only or
active surveillance (AS)/watchful waiting (WW). Five men
received chemotherapy (CT) only as primary treatment and
93 did not respond to treatment questions; these 98 men were
excluded from analyses. Men who received ADT at question-
naire completion were defined as ‘current ADT’. Responders
were classified as ‘CT treated’ if they ever received CT. All
participants had survived at least 2 years post-diagnosis; there-
fore, those currently receiving ADT [20] and treated with CT
were considered as having advanced/recurrent disease.
Survivors were grouped according to length of time since
diagnosis: <5 years, 5–9.9 years and ≥10 years post-diagnosis,
corresponding to short, long and long-term survivors,
respectively.
Questionnaire data were linked with cancer registration da-
ta to obtain date of diagnosis, clinical stage at diagnosis
(Tumour-Lymph Node-Metastasis (TNM) classification, ver-
sion 5) and Gleason grade (GG) at diagnosis (low 2–4, medi-
um 5–7, high 8–10).
Statistical analysis
Analyses were performed using STATAv13.1 (StataCorp LP,
2013). Where more than 5 % of respondents declined to an-
swer a question, a ‘not reported’ category was included.
Prevalence of depression, anxiety and stress was compared
by mode of detection (PSA tested/clinically detected) using t
tests. Chi-square tests were used to investigate associations
between mode of detection and socio-demographic and
clinical characteristics. Prevalence of depression, anxiety and
stress by time since diagnosis was also investigated by chi-
square tests.
The primary outcome variables were depression, anxiety
and stress. A three-stage process was used for model fitting.
Firstly, a univariate odds ratio (OR) was computed for associ-
ation between mode of detection and each psychological out-
come. Socio-demographic and clinical characteristics likely
differ between those with PSA-detected and clinically detect-
ed prostate cancer [21]; therefore, clinical (GG, stage and co-
morbidities at diagnosis, family history of prostate cancer and
treated for depression) and socio-demographic (age at diagno-
sis, marital status, living alone, educational attainment, em-
ployment status at questionnaire completion, jurisdiction and
time since diagnosis) factors were considered as potential con-
founders of associations between mode of detection and psy-
chological wellbeing.
In the second stage, socio-demographic and clinical vari-
ables significant at the 5 % level in univariate analyses were
considered for inclusion in models for depression, anxiety and
stress. Variables significant at the 5 % level were retained.
These risk estimates were termed ‘adjusted ORs (AOR)’.
Primary treatments and adverse physical effects experi-
enced may also differ between men with PSA-detected and
clinically detected cancer. Therefore, in the third stage, the
AOR for mode of detection was further adjusted by individu-
ally fitting primary treatment(s) received, current ADT, CT
treated and each ongoing adverse physical effect, to the ad-
justed models for depression, anxiety and stress. These vari-
ables were fitted individually because of concerns regarding
collinearity and the potential for over-adjustment. These risk
estimates were termed ‘multivariate ORs (MVOR)’.
Sensitivity analyses were conducted where all men who (i)
completed questionnaires by telephone (n = 60), (ii) were
treated for depression post-diagnosis (n = 167) and (iii) had
evidence of advanced/recurrent disease (n = 721) were re-
moved, and adjusted and multivariate models were rerun.
Results
The response rate was 54 % (3348/6262) when men discov-
ered to be ineligible following questionnaire dispatch (e.g.
recent death, incorrect address; n = 297) were removed from
the denominator. Men fromRoI and those whowere ≤59 years
at diagnosis were significantly more likely to respond than
older men and those from NI (Supplementary Table 1) [16].
Significantly more respondents than non-respondents were
staged and graded (p < 0.001). No significant difference in
response was observed by time since diagnosis.
Of all respondents, 1978 (59 %) had PSA-detected
and 1331 (40 %) had clinically detected prostate cancer
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Table 1 Characteristics of the respondents overall and grouped by mode of detection (asymptomatic PSA-tested and symptomatic clinically detected
prostate cancer) with chi-squared p values
All respondents PSA detected/asymptomatica Clinically detected/symptomatica
N = 3348 N = 1978 N = 1331
N (%) N (%) N (%)
Jurisdiction RoI 2338 (70 %) 1538 (78 %) 766 (58 %)
NI 1010 (30 %) 440 (22 %) 565 (42 %)***
Age at diagnosis (years) ≤59 799 (24 %) 514 (26 %) 276 (21 %)
60–69 1631 (49 %) 953 (48 %) 662 (50 %)
≥70 918 (27 %) 511 (26 %) 393 (29 %)***
Time since diagnosis <5 years 1614 (48 %) 990 (50 %) 606 (46 %)
5–9.9 years 1075 (32 %) 656 (33 %) 407 (31 %)
≥10 years 659 (20 %) 332 (17 %) 318 (24 %)***
Marital status Married/cohabiting 2753 (82 %) 1638 (83 %) 1098 (83 %)
Not married 558 (17 %) 328 (17 %) 223 (17 %)
Not reported 37 (1 %) 12 (0.6 %) 10 (1.0 %)
Highest educational level attained Primary 1187 (36 %) 618 (31 %) 557 (42 %)
Secondary 1122 (34 %) 729 (37 %) 387 (29 %)
Tertiary 899 (27 %) 562 (28 %) 334 (25 %)
Not reported 140 (4 %) 69 (4 %) 53 (4 %)***
Employment statusb Employed 1124 (34 %) 715 (36 %) 399 (30 %)
Retired 336 (12 %) 228 (12 %) 154 (12 %)
NAd 1802 (54 %) 1014 (51 %) 765 (58 %)
Not reported 36 (1 %) 21 (1 %) 13 (1.0 %)**
Family history of prostate cancer Yes 791 (24 %) 500 (26 %) 288 (22 %)
No 2448 (73 %) 1434 (74 %) 998 (78 %)
Not reported 109 (3 %) 44 (2 %) 45 (3 %)*
Comorbidity at diagnosis None 1476 (44 %) 941 (48 %) 513 (39 %)
Any 1872 (56 %) 1037 (52 %) 818 (62 %)***
Treated for depressionc Yes 176 (5 %) 78 (4 %) 89 (7 %)
No 3181 (95 %) 1900 (96 %) 1242 (93 %)***
Gleason grade at diagnosis Low (≤6) 212 (6 %) 116 (6 %) 90 (7 %)
Medium (7–8) 2186 (65 %) 1356 (69 %) 808 (61 %)
High (8–10) 625 (19 %) 332 (17 %) 288 (22 %)
Unknown 325 (10 %) 174 (9 %) 145 (11 %)***
Clinical stage at diagnosis I 18 (1 %) 8 (0.4 %) 10 (1.0 %)
II 1875 (56 %) 1254 (63 %) 599 (45 %)
III 463 (14 %) 233 (12 %) 226 (17 %)
IV 141 (4 %) 51 (3 %) 88 (7 %)
Unknown 851 (25 %) 432 (22 %) 408 (31 %)***
Primary treatment RP 934 (28 %) 607 (31 %) 316 (25 %)
EBRTwith concurrent ADT 591 (18 %) 358 (19 %) 232 (18 %)
EBRTwithout concurrent ADT 1127 (34 %) 652 (34 %) 463 (36 %)
BT 124 (4 %) 104 (5 %) 20 (2 %)
ADT 310 (9 %) 137 (7 %) 167 (13 %)
AS/WW 164 (5 %) 82 (4 %) 79 (6 %)***
Current ADTb Yes 657 (20 %) 317 (16 %) 338 (25 %)
No/not reported 2691 (80 %) 1661 (84 %) 993 (75 %)***
CT treated Yes 64 (2 %) 25 (1 %) 38 (3 %)
No/not reported 3284 (98 %) 1953 (99 %) 1293 (97 %)**
Incontinenceb Ongoing 538 (16 %) 274 (14 %) 258 (19 %)
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(Table 1). This information was missing for 1 % of
respondents (n = 39).
The percentage of men with PSA-detected prostate cancer
was significantly higher among men who were from RoI,
younger at diagnosis, employed at questionnaire completion
and <10 years post-diagnosis and had secondary- or third-
level education, a family history of prostate cancer and with-
out comorbidities at diagnosis (Table 1). PSA-detected men
were significantly more often diagnosed with stage II and
medium GG cancers than clinically detected men. Primary
treatment(s) received varied significantly with mode of detec-
tion; a higher percentage of PSA-detected men received RP or
BT, while a higher percentage of clinically detected men were
treated with ADT alone. The percentage of men currently
receiving ADT, or treated with CT, was significantly higher
among men with PSA-detected than clinically detected dis-
ease. Clinically detected men significantly more often report-
ed ongoing urinary incontinence, hot flashes, bowel problems,
gynecomastia and fatigue than survivors with PSA-detected
disease; only impotence was significantly higher among men
diagnosed with PSA-detected prostate cancer. Loss of libido
did not differ significantly by mode of diagnosis.
Overall, prevalence of depression, anxiety and stress among
respondents was 17 % (95 % CI 15.2 %, 17.9 %), 16 % (95 %
CI 15.1 %, 17.7 %) and 11 % (95 % CI 9.5 %, 11.7 %),
respectively (Fig. 1). Prevalence of each negative emotional
Table 1 (continued)
All respondents PSA detected/asymptomatica Clinically detected/symptomatica
N = 3348 N = 1978 N = 1331
N (%) N (%) N (%)
No/not reported 2810 (84 %) 1704 (86 %) 1073 (81 %)***
Impotenceb Ongoing 1960 (59 %) 1207 (61 %) 739 (56 %)
No/not reported 1388 (41 %) 771 (39 %) 592 (44 %)**
Loss of libidob Ongoing 1572 (47 %) 917 (46 %) 646 (49 %)
No/not reported 1776 (53 %) 1061 (54 %) 685 (51 %)
Bowel problemsb Ongoing 496 (15 %) 247 (13 %) 244 (18 %)
No/not reported 2852 (85 %) 1731 (87 %) 1087 (82 %)***
Gynecomastiab Ongoing 350 (10 %) 181 (9 %) 167 (13 %)
No/not reported 2998 (90 %) 1797 (91 %) 1164 (87 %)**
Hot flashes/sweatsb Ongoing 582 (17 %) 274 (14 %) 305 (23 %)
No/not reported 2766 (83 %) 1704 (86 %) 1026 (77 %)***
Fatigueb Ongoing 765 (23 %) 376 (19 %) 385 (29 %)
No/not reported 2583 (77 %) 1602 (81 %) 946 (71 %)***
RoI Republic of Ireland, NI Northern Ireland; primary treatment hierarchy: RP radical prostatectomy, EBRT external beam radiotherapy, ADT androgen
deprivation therapy, BT brachytherapy, AS/WW active surveillance/watchful waiting, CT chemotherapy
*p < 0.05; **p < 0.01; ***p < 0.001
aMenwere classified as having asymptomatic ‘PSA-detected’ disease if they answered ‘yes’ to any of the following statements: ‘I had no symptoms and
my GP offered to test my PSA as part of a general health check’ or ‘I had no symptoms and I asked my GP to measure my PSA’, and as having
symptomatic ‘clinically detected’ disease if they answered ‘yes’ to either of the following statements: ‘I attended my GP with urinary symptoms (e.g.
urinating frequently, blood in urine)’ or ‘I attended my GPwith other symptoms (e.g. back pain, joint pain)’. Men who endorsed both asymptomatic and
symptomatic statements (n = 171; 5 %) were coded as symptomatic
bAt the time of questionnaire completion
cTreated for depression post-prostate cancer diagnosis
d Not working at the time of diagnosis or at questionnaire completion
0%
5%
10%
15%
20%
25%
Depression Anxiety Stress
All responders
PSA-detected
Clinically-detected
*
**
Fig. 1 Prevalence of depression, anxiety and stress overall among
prostate cancer survivors, and by mode of detection (PSA-detected and
clinically detected prostate cancer), with 95 % confidence intervals
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state did not vary significantly with time since diagnosis (de-
pression p = 0.958; anxiety p = 0.380 and stress; p = 0.461).
Survivors with PSA-detected disease had significantly
lower prevalence of depress ion (14 vs 21 %;
p < 0.001), anxiety (14 vs 21 %; p < 0.001) and stress
(9 vs 14 %; p < 0.001) than those with clinically de-
tected disease (Fig. 1). Clinically detected survivors
were significantly more likely to have been treated for
depression post-prostate cancer diagnosis than PSA-
detected survivors (7 vs 4 %; p = 0.001)..
In univariate analysis, mode of detection was significantly
associated with each negative psychological state; survivors
with clinically detected disease had significantly higher risks
of depression, anxiety and stress than those with PSA-detected
disease (Table 2).
Risk of depression, anxiety and stress was highest among
survivors who were unmarried, unemployed and fromNI; had
primary-level education and ≥1 comorbidity at diagnosis; and
were treated for depression post-diagnosis. Survivors
≤59 years at diagnosis had higher odds of depression and
stress than older men. Odds of depression and anxiety were
significantly higher in those who lived alone, compared to
those who did not.
In adjusted models containing significant socio-
demographic and clinical factors, mode of diagnosis remained
significantly associated with psychological wellbeing; clini-
cally detected men had higher odds of depression
(AOR = 1.46, 95 % CI 1.18, 1.80), anxiety (AOR = 1.36,
95 % CI 1.09, 1.68) and stress (AOR = 1.43, 95 % CI 1.11,
1.85) than those with PSA-detected disease (Table 2).
Primary treatment(s) (p = 0.047) and having received
CT (p = 0.035) were significantly associated with in-
creased odds of anxiety, and current ADT was associat-
ed with increased odds of anxiety (p = 0.015) and stress
(p < 0.001). Risk of each negative psychological state
was significantly higher in men who experienced each
ongoing adverse physical effect than those who did not,
and risk increased significantly with number of adverse
physical effects experienced (all p values <0.05; data
not shown).
When each treatment and adverse physical effect variable
was added individually to adjusted models, mode of detection
remained significantly associated with depression (range of
MVORs 1.35 to 1.49) and anxiety (range of MVORs 1.27 to
1.38; table 3). Mode of detection also remained significantly
associated with stress when each treatment and adverse effect
variable was added to the adjusted model (range of MVORs
1.36 to 1.44), except for fatigue and total number of adverse
effects.
Mode of detection remained significant in both ad-
justed and multivariate models of depression, anxiety
and stress in each of the three sensitivity analyses (data
not shown).
Discussion
To inform rational decision-making around PSA testing, it is
essential to have a comprehensive understanding of conse-
quent benefits and risks. To extend understanding in this area,
we investigated—for the first time to our knowledge—wheth-
er long-term psychological wellbeing differed between pros-
tate cancer survivors detected through PSA testing and those
who were not. In our large, population-based study of men 2
to 18 years post-diagnosis, we found that those diagnosed
with asymptomatic PSA-detected prostate cancer had signifi-
cantly reduced odds of depression, anxiety and stress com-
pared to men with symptomatic clinically detected disease,
after controlling for socio-demographic and clinical factors.
In this study, men with PSA-detected prostate cancer were
younger and had lower-stage and lower-grade disease and
fewer comorbidities at diagnosis than those with clinically
detected disease. This is similar to characteristics of screened
populations in randomised controlled screening trials [22, 23].
However, we adjusted associations between mode of detec-
tion and psychological wellbeing for these variables; there-
fore, they cannot explain our findings.
Screening can lead to less aggressive treatment for early
screen-detected cancers, e.g. breast cancer [24], but this is
not the case for PSA-detected prostate cancer. Indeed, only
5 % of survivors in this dataset were managed by active
surveillance/watchful waiting. Different primary treatment
patterns were observed between men with PSA-detected and
clinically detected disease, and primary treatment was signif-
icantly associated with increased risk of anxiety (but not de-
pression or stress), following adjustment for socio-
demographic and clinical factors. There is limited and incon-
sistent information regarding treatment effects on prostate
cancer survivors’ psychological health [25–28]. Men current-
ly receiving ADT had significantly increased odds of anxiety
and stress, and anxiety risk was increased in those treated with
CT. These men are likely to have recurrences/disease progres-
sion [20], which increases risk of poor psychological health
among men with prostate cancer [29]. When we adjusted for
treatments, mode of diagnosis remained significantly associ-
ated with increased risk of depression, anxiety and stress, so
differences in treatment between PSA-detected and clinically
detected men cannot explain our results.
Risk of all three negative psychological states was signifi-
cantly higher in survivors who experienced each ongoing ad-
verse physical effect, compared to those who did not.
Furthermore, risk of depression, anxiety and stress increased
with the number of adverse physical effects. This finding is in
agreement with previous studies which found that loss of pre-
vious abilities post-treatment increased odds of poor psycho-
logical wellbeing among prostate cancer survivors [26, 30].
Indeed, loss of quality-adjusted life years due to long-term
adverse effects of prostate cancer decreased the benefit of
2302 Support Care Cancer (2016) 24:2297–2307
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PSA screening in the ERSPC trial [22]. Within this dataset,
survivors with PSA-detected disease less often reported ongo-
ing adverse physical effects, except for impotence, than men
with clinically detected disease. Furthermore, men with PSA-
detected cancer were also at lower risk of poor psychological
health when models were adjusted for each adverse physical
effect, or number of adverse effects, than those with clinically
detected disease.
So how might we explain our findings? Firstly, results may
be explained by (self) selection, i.e. systematic differences in
men who have PSA tests and those who do not. The ‘healthy
user effect’, i.e. the propensity of healthier patients to seek out
and initiate preventative therapies, is one possible explanation.
For example, Brookhart et al. [31] found that people who were
adherent to statin therapy were more likely to have cancer
screening tests, including PSA tests, than those who were
not adherent. This they hypothesise may be due to (i) adherent
patients being ‘more health seeking’ and therefore more likely
to seek or agree to take other preventative interventions and
tests and/or (ii) differences in health status (physical and cog-
nitive) between the two groups, with those who are adherent
being healthier. Additionally, men with poorer psychological
health have been found to be less likely to have PSA tests
[32–34].Moreover, those predisposed to poorer psychological
health are also predisposed to poor wellbeing throughout their
disease trajectory [35]. Therefore, despite adjusting for a range
Table 3 Multivariate odds ratios (MVOR) with 95 % confidence inter-
vals and likelihood ratio p values for mode of detection (PSA detected
and clinically detected). MVORs for mode of detection are adjusted for
significant socio-demographic and clinical factors (Table 2) and individ-
ually for treatment and adverse physical effects variables
Mode of detectiona Depression Anxiety Stress
Multivariate OR
(95 % CI)
Multivariate OR
(95 % CI)
Multivariate OR
(95 % CI)
Prostate cancer treatments
Primary treatment(s)b PSA detected 1 1 1
Clinically detected 1.44 (1.16, 1.79)** 1.31 (1.05, 1.63)* 1.41 (1.09, 1.82)*
Current ADT PSA detected 1 1 1
Clinically detected 1.44 (1.16, 1.80)** 1.33 (1.07, 1.65)* 1.39 (1.07, 1.80)*
Treated with CT PSA detected 1 1 1
Clinically detected 1.45 (1.18, 1.80)** 1.33 (1.07, 1.66)* 1.42 (1.10, 1.83)*
Adverse physical effects ongoing at questionnaire completion
Incontinence PSA detected 1 1 1
Clinically detected 1.40 (1.13, 1.73)* 1.27 (1.02, 1.58)* 1.36 (1.05, 1.76)*
Impotence PSA detected 1 1 1
Clinically detected 1.49 (1.20, 1.84)** 1.38 (1.11, 1.72)* 1.44 (1.12, 1.87)*
Loss of libido PSA detected 1 1 1
Clinically detected 1.46 (1.18, 1.80)** 1.37 (1.10, 1.70)* 1.42 (1.10, 1.84)**
Bowel problems PSA detected 1 1 1
Clinically detected 1.42 (1.15, 1.76)** 1.33 (1.07, 1.65)* 1.37 (1.06, 1.77)*
Gynacomastia PSA detected 1 1 1
Clinically detected 1.44 (1.17, 1.78)** 1.35 (1.09, 1.67)* 1.41 (1.09, 1.83)*
Hot flashes/sweats PSA detected 1 1 1
Clinically detected 1.43 (1.15, 1.76)** 1.35 (1.09, 1.67)* 1.36 (1.05, 1.76)*
Fatigue PSA detected 1 1 1
Clinically detected 1.35 (1.09, 1.68)** 1.28 (1.03, 1.60)* 1.29 (0.99, 1.67)
Total number adverse physical effects PSA detected 1 1 1
Clinically detected 1.35 (1.09, 1.68)* 1.28 (1.03, 1.60)* 1.27 (0.98, 1.65)
*p < 0.05; **p < 0.01; ***p < 0.001
aMenwere classified as having asymptomatic ‘PSA-detected’ disease if they answered ‘yes’ to any of the following statements: ‘I had no symptoms and
my GP offered to test my PSA as part of a general health check’ or ‘I had no symptoms and I asked my GP to measure my PSA’, and as having
symptomatic ‘clinically detected’ disease if they answered ‘yes’ to either of the following statements: ‘I attended my GP with urinary symptoms (e.g.
urinating frequently, blood in urine)’ or ‘I attended my GPwith other symptoms (e.g. back pain, joint pain)’. Men who endorsed both asymptomatic and
symptomatic statements (n = 171; 5 %) were coded as symptomatic
bPrimary treatment: a hierarchical variable defined as RP, radical prostatectomy with/without other treatments; ERBT, external beam radiotherapy; BT,
brachytherapy; ADT, androgen deprivation therapy; AS/WW, active surveillance/watchful waiting; and CT, chemotherapy
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of socio-demographic and clinical variables known to be as-
sociated with likelihood of PSA testing, it is possible that our
findings are due to unmeasured confounders between men
with PSA-detected and clinically detected prostate cancer,
for example their psychosocial functioning and their
relationships.
Another possibility is that those diagnosed with PSA-
detected and clinically detected disease adjusted to their
‘new normal’ differently. Men diagnosed with PSA-detected
prostate cancer, because they were asymptomatic, may con-
sider themselves ‘lucky’ their cancer was discovered. They
may also attribute their survival to treatment received and be
grateful for being cured [36]. We speculate that such feelings
of good fortune could translate into better psychological
wellbeing.
Many issues have been shown to be associated with this
adjustment including self-efficacy [37], perceived stress [37],
dyadic adjustment and threat appraisal [38]. Furthermore, a
person’s appraisal of the significance of an event or stress,
e.g. a cancer diagnosis, is influenced by their characteristics
and their environment; this in turn influences their subsequent
coping style [39]. Coping style, i.e. the thoughts and behav-
iours used to regulate distress, is central to the adjustment
process [37–40]. Men with prostate cancer use different cop-
ing strategies depending on age, PSA level and stage [40, 41].
Younger men, with lower PSA levels were more likely to use
positive coping skills including problem-solving and self-re-
liance, which in turn were associated with lower levels of
depression [40]. More negative coping skills, including cog-
nitive avoidance, have been shown to be used by men with
later-stage disease, and these predict anxiety [41]. Therefore,
coping strategies may differ between men with PSA-detected
and clinically detected prostate cancer in such a way as to
result in better psychological wellbeing in the former group.
Finally, adequate communication between men with prostate
cancer, their partners and their medical teams is also important
in adjustment [42], and those requesting and/or accepting PSA
tests may be most likely to engage with their doctors and/or
partners.
Overall, however, these explanations are largely specula-
tive and further research, including longitudinal investigations
of the evolution of negative psychological states, and associ-
ated factors, following men diagnosed with symptomatic,
clinically detected and asymptomatic PSA-detected prostate
cancer from diagnosis through the survivorship continuum
are needed. Furthermore, we support the recommendations
by the National Comprehensive Cancer Network and others
that patients and survivors with (prostate) cancer should be
screened regularly for psychological distress, ‘the sixth vital
sign’, and referred for appropriate supportive care.
Interventions have been shown to reduce or alleviate negative
psychological symptoms among men with prostate cancer
[43]; however, in light of our findings, we suggest that the
effect of these supportive care interventions onmen diagnosed
with clinically detected and PSA-detected prostate cancer
should be investigated.
Prevalence of depression and anxiety among survivors did
not vary significantly with time since diagnosis, suggesting
that it may be persistent for some men post-treatment.
Prevalence of depression and anxiety in this dataset were
similar, although slightly lower than that previously reported
(depression 18.4 %, anxiety 18.5 % [28]. Comparisons be-
tween studies are difficult due to variations in psychological
assessment tools used and socio-demographic, clinical and
treatment characteristics of datasets. Notwithstanding this,
prevalence of depression among prostate cancer survivors
overall was higher than the 10 % reported in the Irish popu-
lation ≥50 years [44], and among survivors with clinically
detected prostate cancer, prevalence of depression (21 vs
18.3 %) and anxiety (21 vs 5.6 %) was higher than that
among a UK adult population [19].
This population-based study extends current knowledge
about the psychological health of prostate cancer survivors;
a meta-analysis of 27 studies across all phases of the disease
trajectory included 3087 men post-treatment; [28] this study
alone involved 3348 survivors post-treatment. It is the first to
investigate the effect of mode of detection on prostate cancer
survivors’ psychological wellbeing. It is the first time all com-
mon treatments have been directly compared for their effect
on the psychological health of survivors. Furthermore, we
used a validated instrument to investigate psychological
wellbeing [18]. However, the study was cross-sectional and
measured depression, anxiety and stress in the week prior to
questionnaire completion; therefore, we do not know how
many men become depressed, anxious or stressed at different
stages during survivorship and who had recovered by the time
of questionnaire completion. We did not have information on
the pre-diagnostic history of, or predisposition to, depression,
anxiety or stress. Missing data in DASS-21 means that prev-
alence of depression, anxiety and/or stress may have been
over- or underestimated, and non-responders may have dif-
fered in the effect of mode of detection on their psychological
wellbeing than responders. Finally, we based our analysis on
self-reported treatment(s) and mode of detection and, like all
patient-reported outcomes research, there is a possibility of
recall bias within our study [45].
In this study, more than one in six prostate cancer survivors
experienced poor psychological health and risk was signifi-
cantly higher in men with clinically detected disease. PSA
testing is common in most developed countries, and some
advocate the implementation of prostate cancer screening
programmes [2–4]. To inform rational decision-making, it is
imperative that all potential benefits and risks of testing are
assessed; this study fills a gap in the evidence base around
PSA testing. Irrespective of PSA testing policy, the relatively
high prevalence of negative psychological states among
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survivors in this study means that a ‘risk-adapted approach’
should be implemented to screen survivors most at risk of
psychological morbidity for psychological health. Our find-
ings suggest that mode of detection could be considered as a
risk stratum in such an approach. This, together with increased
utilisation of medications and/or cognitive interventions to
improve psychological wellbeing, may enhance clinical out-
comes and improve psychological wellbeing among prostate
cancer survivors.
In conclusion, prostate cancer survivors diagnosed with
asymptomatic PSA-detected disease were at lower risk of de-
pression, anxiety and stress during survivorship than those
with symptomatic clinically diagnosed disease, following ad-
justment for socio-demographic and clinical factors. Our find-
ings require further research to understand the underlying rea-
sons. These findings contribute to the ongoing debate on the
benefits and risks of PSA testing and may be considered by
policy makers formulating population-based prostate cancer
screening policies.
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